Menarini Group

News

NICE backs wider NHS use of multiple myeloma drug Nexpovio

More than 1,000 people with incurable blood cancer multiple myeloma could be eligible for treatment with Menarini Stemline UK’s Nexpovio after NICE backed NHS use of the d

News

Menarini brings oral SERD to Europe with Orserdu okay

Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the

News

Stemline first to market with oral SERD for breast cancer

Menarini subsidiary Stemline Therapeutics has won FDA approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs that provide a new form

News

Radiology technician examens mammography test on location

After setbacks for Roche and Sanofi, AZ scores oral SERD win

AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

News

Roche's oral SERD giredestrant fails breast cancer trial

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme

NICE backs wider NHS use of multiple myeloma drug Nexpovio

Menarini brings oral SERD to Europe with Orserdu okay

Stemline first to market with oral SERD for breast cancer

After setbacks for Roche and Sanofi, AZ scores oral SERD win

End of the line for Sanofi's SERD amcenestrant as it fails f...

Roche's oral SERD giredestrant fails breast cancer trial

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Menarini Group

Editor's Picks